Stock AB AB SCIENCE
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases AB Science

Equities

AB

FR0010557264

Real-time Euronext Paris
Other stock markets
 12:40:35 29/04/2024 BST 		5-day change 1st Jan Change
1.926 EUR -0.52% Intraday chart for AB Science -2.70% -45.32%
04-04 AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada MT
04-03 AB Science: reconsideration possible for masitinib in ALS CF

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
GL
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
AQ
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
GL
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
AQ
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
GL
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GL
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
GL
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
GL
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
GL
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
GL
AB Science will host a live webcast on Thursday November 30, 2023, from 3pm to 4pm CET, to present the masitinib development program in sickle cell disease
GL
AB Science: The clinical development of masitinib in sickle cell disease is among the 19 winning projects under the sixth call for “Hospital-Inuversity Research in health (RHU)”
GL
AB Science today reports its revenues for the first half of 2023 and provides an update on its activities
GL
AB Science provides an update on the EMA timetable for examination of the masitinib marketing authorization application in ALS
GL
AB Science receives Notice of Allowance for European patent covering masitinib in the treatment of metastatic castrate refractory prostate cancer (mCRPC)
GL
AB Science announces issuance of a Canadian patent for masitinib in the treatment of ALS with protection until 2037
GL
AB Science summarizes key messages from its participation to a panel discussion at the 2023 ALS Drug Development Summit
GL
AB Science announces that Health Canada has resumed its review of the New Drug Submission for masitinib in amyotrophic lateral sclerosis, following issuance of a screening acceptance letter
GL
AB Science reports its revenues for the year 2022 and provides an update on its activities
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AB Stock
  4. News AB Science
  5. Press Releases